Literature DB >> 14638349

A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis.

Bo Shen1, Kenneth M Shermock, Victor W Fazio, Jean-Paul Achkar, Aaron Brzezinski, Charles L Bevins, Marlene L Bambrick, Feza H Remzi, Bret A Lashner.   

Abstract

OBJECTIVE: Pouchitis is often diagnosed based on symptoms and empirically treated with antibiotics (treat-first strategy). However, symptom assessment alone is not reliable for diagnosis, and an initial evaluation with pouch endoscopy (test-first strategy) has been shown to be more accurate. Cost-effectiveness of these strategies has not been compared. The aim of this study was to compare cost-effectiveness of different clinical approaches for patients with symptoms suggestive of pouchitis.
METHODS: Pouchitis was defined as pouchitis disease activity index scores > or =7. The frequency of pouchitis in symptomatic patients with ileal pouch was estimated to be 51%; the efficacy for initial therapy with metronidazole (MTZ) and ciprofloxacin (CIP) was 75% and 85%, respectively. Cost estimates were obtained from Medicare reimbursement data.
RESULTS: Six competing strategies (MTZ trial, CIP trial, MTZ-then-CIP trial, CIP-then-MTZ trial, pouch endoscopy with biopsy, and pouch endoscopy without biopsy) were modeled in a decision tree. Costs per correct diagnosis with appropriate treatment were $194 for MTZ trial, $279 for CIP trial, $208 for MTZ-then-CIP trial, $261 for CIP-then-MTZ trial, $352 for pouch endoscopy with biopsy, and $243 for pouch endoscopy without biopsy. Of the two strategies with the lowest cost, the pouch endoscopy without biopsy strategy costs $50 more per patient than the MTZ trial strategy but results in an additional 15 days for early diagnosis and thus initiation of appropriate treatment (incremental cost-effectiveness ratio $3 per additional day gained). The results of base-case analysis were robust in sensitivity analyses.
CONCLUSIONS: Although the MTZ-trial strategy had the lowest cost, the pouch endoscopy without biopsy strategy was most cost-effective. Therefore, based on its relatively low cost and the avoidance of both diagnostic delay and adverse effects associated with unnecessary antibiotics, pouch endoscopy without biopsy is the recommended strategy among those tested for the diagnosis of pouchitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638349     DOI: 10.1111/j.1572-0241.2003.07710.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Diagnosis and management of pouchitis and ileoanal pouch dysfunction.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

2.  Pouchitis disease activity index (PDAI) does not predict patients with symptoms of pouchitis who will respond to antibiotics.

Authors:  Mohei Kohyama; Yoshio Takesue; Hiroki Ohge; Yoshiaki Murakami; Fumio Shimamoto; Taijiro Sueda
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

3.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

4.  Acute pouchitis: the condition that time forgot about.

Authors:  Jonathan P Segal; Maia Kayal; Zaid Ardalan; Mayur Garg; Miles Sparrow; Edward Barnes
Journal:  Therap Adv Gastroenterol       Date:  2022-09-22       Impact factor: 4.802

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.